Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Leuk Lymphoma. 2011 Oct;52(10):1970–1979. doi: 10.3109/10428194.2011.582202

Figure 1.

Figure 1

A. 007, a TLR7/8 agonist, potently activates the NK cells of Sezary syndrome patients and upregulates CD69 expression.

PBMC from Sezary syndrome patients were cultured with media, IFN-γ, or IL-15 for 4h followed by 20h stimulation with 007, a TLR7/8 agonist. Cells were then harvested, stained with appropriate antibodies and analyzed for the expression of CD69 on CD56/CD16 NK cells. Data represent mean ± standard deviation of tested individuals and are presented as a percentage of NK cells positive for CD69 (n=12).

B and C. IFN-γ and IL-15 significantly upregulate the 007-induced cell-mediated cytolytic killing activity of the PBMC of Sezary syndrome patients against tumor cell lines.

PBMC from patients were stimulated as described in Figure 1A, followed by a 4h Cr51 assay using as targets either K562 leukemic cells (B) or the SEZ4, a Sezary-derived T cell line (C). Data represent mean ± standard deviation of tested individuals (n=9)